Protagonist Therapeutics, Inc. $PTGX Shares Acquired by Scientech Research LLC

Scientech Research LLC increased its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 51.6% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,271 shares of the company's stock after purchasing an additional 6,217 shares during the period. Scientech Research LLC's holdings in Protagonist Therapeutics were worth $884,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. New Vernon Capital Holdings II LLC raised its position in shares of Protagonist Therapeutics by 11,271.9% during the 1st quarter. New Vernon Capital Holdings II LLC now owns 348,095 shares of the company's stock valued at $16,834,000 after purchasing an additional 345,034 shares during the period. Millennium Management LLC raised its position in shares of Protagonist Therapeutics by 283.6% during the 1st quarter. Millennium Management LLC now owns 134,269 shares of the company's stock valued at $6,493,000 after purchasing an additional 99,269 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Protagonist Therapeutics by 0.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,403 shares of the company's stock valued at $1,810,000 after purchasing an additional 348 shares during the period. EFG Asset Management North America Corp. bought a new stake in shares of Protagonist Therapeutics during the 1st quarter valued at $3,439,000. Finally, Checkpoint Capital L.P. purchased a new position in Protagonist Therapeutics during the first quarter valued at $8,472,000. 98.63% of the stock is currently owned by institutional investors.

Protagonist Therapeutics Stock Down 1.4%

PTGX traded down $0.82 on Friday, reaching $58.86. 685,841 shares of the company traded hands, compared to its average volume of 869,797. Protagonist Therapeutics, Inc. has a one year low of $33.31 and a one year high of $61.89. The firm has a fifty day simple moving average of $55.70 and a two-hundred day simple moving average of $50.77. The company has a market cap of $3.66 billion, a P/E ratio of 84.09 and a beta of 2.22.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.02). Protagonist Therapeutics had a net margin of 24.88% and a return on equity of 8.12%. The company had revenue of $5.55 million for the quarter, compared to the consensus estimate of $8.32 million. On average, equities analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on PTGX. Leerink Partners began coverage on shares of Protagonist Therapeutics in a research note on Friday. They set an "outperform" rating and a $73.00 target price for the company. Leerink Partnrs raised shares of Protagonist Therapeutics to a "strong-buy" rating in a research note on Friday. Citigroup reissued an "outperform" rating on shares of Protagonist Therapeutics in a research note on Thursday, August 7th. Wall Street Zen raised shares of Protagonist Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday, June 8th. Finally, HC Wainwright reissued a "buy" rating and issued a $80.00 price objective on shares of Protagonist Therapeutics in a research note on Tuesday, June 3rd. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $67.73.

Insider Activity

In related news, CEO Dinesh V. Ph D. Patel sold 10,415 shares of the business's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $54.78, for a total transaction of $570,533.70. Following the completion of the transaction, the chief executive officer owned 520,603 shares in the company, valued at $28,518,632.34. The trade was a 1.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director William D. Waddill sold 4,000 shares of the business's stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $59.25, for a total transaction of $237,000.00. Following the transaction, the director owned 9,130 shares of the company's stock, valued at approximately $540,952.50. This trade represents a 30.46% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 66,859 shares of company stock valued at $3,687,577. Company insiders own 4.90% of the company's stock.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.